IL2 and teratocarcinoma: A complete tumor eradication was reported when L19-IL-2 was administered in combination with CTLA-4 blockade in two syngeneic immunocompetent mouse models of teratocarcinoma and colon carcinoma; in the latter model, responder mice to this combination treatment were resistant to tumor re-challenge (22).